445 completed, 80 unknown, 67 terminated, 25 recruiting. 655 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 655 | Completed 445, Unknown 80, Terminated 67, Recruiting 25, Active not recruiting 13, Withdrawn 13, Not yet recruiting 7, Enrolling by invitation 4, Suspended 1 |
Follow Sexually Transmitted Diseases: new trials by email Literature Review of Sexually Transmitted Diseases trials Research Report on Sexually Transmitted Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study Field-based LA-CAB/RPV - HIV Infection | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | 40 | 2027-01-01 | 2026-10-26 |
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | 40 | 2026-10-05 | 2026-10-06 |
| Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV Vaginal estradiol tablets, Vaginal moisturizer - Menopausal Complaints, Vaginal Atrophy | Phase 4 | Not yet recruiting | Albert Einstein College of Medicine | 62 | 2026-09-01 | 2026-07-28 |
| NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection - HIV Infections, Opioid Use Disorder | Phase 4 | Not yet recruiting | Duke University | 450 | 2026-09-01 | 2026-08-26 |
| ESCUDDO Long Term Follow Up Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine - Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm | Phase 4 | Enrolling by invitation | National Cancer Institute (NCI) | 13700 | 2026-08-11 | 2026-09-22 |
| Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV Tirzepatide - Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease | Phase 4 | Enrolling by invitation | National Taiwan University Clinical Trial Center | 60 | 2026-06-25 | 2026-07-20 |
| REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE Bictegravir, emtricitabine, and tenofovir alafenamide - HIV -1 Infection, HIV (Human Immunodeficiency Virus) | Phase 4 | Recruiting | CAN Community Health | 200 | 2026-06-17 | 2026-09-03 |
| Menopausal HT for Women Living With HIV (HoT) Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel - HIV Infection, Menopause | Phase 4 | Recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 105 | 2026-04-09 | 2026-05-22 |
| Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Doxycycline hyclate delayed released 200 mg, Doxycycline hyclate delayed released 200 mg weekly, Per standard of care with quarterly STI testing/treatment and sexual health counseling - Gonorrhea, Chlamydia | Phase 4 | Recruiting | Westat | 760 | 2026-02-27 | 2026-10-16 |
| Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years bivalent HPV vaccine, 9-valent HPV vaccine - HPV Infection | Phase 4 | Active not recruiting | Zhejiang Provincial Center for Disease Control and Prevention | 400 | 2025-12-20 | 2026-06-11 |
| OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa Artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ) - Malaria, Hiv | Phase 4 | Recruiting | Yale University | 380 | 2025-12-18 | 2026-02-04 |
| Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM WHO-recommended periodic presumptive treatment, Doxycycline post-exposure prophylaxis - Gonorrhea Male, Chlamydia (Male) | Phase 4 | Active not recruiting | University of Washington | 2900 | 2025-10-29 | 2026-11-02 |
| Got Doxy- 'Flipping the Script' on STI PEP Doxycycline monohydrate 200 mg, Observation - Sexually Transmitted Infections (STI) | Phase 4 | Recruiting | Emory University | 200 | 2025-10-13 | 2026-04-30 |
| The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand. Doxycycline (200mg/day) - Syphilis Infection, Gonorrhea | Phase 4 | Recruiting | Bangrak STIs Center | 400 | 2025-10-06 | 2026-02-09 |
| MAPS PrEP Van Study Pre-Exposure Prophylaxis (PrEP) - HIV Infection | Phase 4 | Completed | Duke University | 7 | 2025-09-17 | 2026-07-24 |
| HIV Prevention With PrEP Among People on Opioid Replacement Therapy Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs - HIV - Human Immunodeficiency Virus | Phase 4 | Recruiting | Cara Spence | 350 | 2025-08-28 | 2025-10-07 |
| Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up Standard Medical Therapy, dual therapy - HIV Infections | Phase 4 | Recruiting | José Antonio Mata Marín | 156 | 2025-07-12 | 2025-08-22 |
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine - HIV Infection, Antiretroviral Therapy | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 78 | 2025-07-10 | 2026-07-01 |
| Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention Multiple Product PrEP Program, Routine Oral PrEP - Hiv | Phase 4 | Recruiting | University of Alabama at Birmingham | 1400 | 2025-06-03 | 2026-07-22 |
Showing 20 of 655. Sign in to see all of them.
HIV Infections (413) · Acquired Immunodeficiency Syndrome (211) · Papillomavirus Infections (33) · Tuberculosis (26) · Hepatitis C (22) · Lipodystrophy (20) · Chlamydia Infections (16) · Gonorrhea (15) · Syphilis (15) · HIV Seropositivity (14) · Herpes Genitalis (14) · Infections (14) · HIV-Associated Lipodystrophy Syndrome (11) · Cardiovascular Diseases (10)
Genital Diseases (655) · Urogenital Diseases (655) · Communicable Diseases (654) · Infections (641) · Sexually Transmitted Diseases, Viral (618) · Virus Diseases (618) · Blood-Borne Infections (572) · Retroviridae Infections (572) · Immunologic Deficiency Syndromes (571) · RNA Virus Infections (571) · Immune System Diseases (570) · Lentivirus Infections (570) · Slow Virus Diseases (211) · HIV Infections (159)
Ritonavir (59) · Lamivudine (57) · Tenofovir (56) · efavirenz (48) · Emtricitabine (46) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (43) · Raltegravir Potassium (41) · Lopinavir (35) · lopinavir-ritonavir drug combination (34) · Nevirapine (30) · Atazanavir Sulfate (28) · Maraviroc (26) · Zidovudine (24) · dolutegravir (23) · Darunavir (22)
Germans Trias i Pujol Hospital (20) · University of Washington (20) · University of California, San Francisco (18) · National Institute of Allergy and Infectious Diseases (NIAID) (15) · ViiV Healthcare (14) · Fundacion SEIMC-GESIDA (13) · Gilead Sciences (13) · GlaxoSmithKline (13) · Hoffmann-La Roche (12) · Kirby Institute (12) · Emory University (11) · Boehringer Ingelheim (9) · University of British Columbia (9) · University of North Carolina, Chapel Hill (9) · Bristol-Myers Squibb (8)
United States (247) · Spain (85) · Canada (36) · South Africa (34) · United Kingdom (29) · Brazil (27) · Uganda (27) · Thailand (26) · France (23) · Puerto Rico (22) · Italy (21) · China (20) · Australia (19) · Netherlands (18) · Mexico (16)
Bonaventura Clotet, MD,PhD (6) · Colleen Kelley, MD, MPH (5) · Anna Wald, MD, MPH (4) · Calvin J Cohen, MD, MSc (4) · David A Cooper, MD (4) · Andrew D Carr, MD (3) · Dominique Costagliola (3) · Igho Ofotokun, MD, MSc (3) · Jared Baeten, MD, PhD (3) · Jihad Slim, MD (3)
PMID 41276263, PMID 22225814, PMID 41701614, PMID 25297720, PMID 32078808, PMID 33857679, PMID 37018493, PMID 38118022, PMID 10218526, PMID 10219064, PMID 11172138, PMID 11188837, PMID 11813503, PMID 11915000, PMID 12594647, PMID 12809582, PMID 13519856, PMID 15577626, PMID 15633090, PMID 15652610, PMID 15750399, PMID 16220084, PMID 16371882, PMID 16394049, PMID 16905024, PMID 17269969, PMID 17302380, PMID 17517949, PMID 17578790, PMID 17615254, PMID 17714677, PMID 18008241, PMID 18090049, PMID 18097218, PMID 18256392, PMID 18284320, PMID 18313637, PMID 18360319, PMID 18395692, PMID 18468575, PMID 18474495, PMID 18520443, PMID 18621575, PMID 18641035, PMID 18653575, PMID 18697216, PMID 18771056, PMID 18781872, PMID 18782780, PMID 18851761
2005 (4), U01AI068632 (4), U01AI068636 (4), 2004 (3), 2008 (3), 2009 (3), 2019 (2), R01AI145971 (2), R01HD068174 (2), R01MH072383 (2), UM1AI068636 (2), 2014 (1), 2016 (1), 2017 (1), 2018 (1)